vs
Side-by-side financial comparison of Ecolab (ECL) and Zoetis (ZTS). Click either name above to swap in a different company.
Ecolab is the larger business by last-quarter revenue ($4.1B vs $2.4B, roughly 1.7× Zoetis). Zoetis runs the higher net margin — 25.3% vs 10.6%, a 14.6% gap on every dollar of revenue. On growth, Ecolab posted the faster year-over-year revenue change (10.0% vs 3.0%). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs 1.0%).
Ecolab Inc., headquartered in Saint Paul, Minnesota, provides products related to water treatment, sanitation, and hygiene, primarily to commercial and industrial customers.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
ECL vs ZTS — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.1B | $2.4B |
| Net Profit | $432.6M | $603.0M |
| Gross Margin | — | 70.2% |
| Operating Margin | 15.3% | 31.9% |
| Net Margin | 10.6% | 25.3% |
| Revenue YoY | 10.0% | 3.0% |
| Net Profit YoY | 1.3% | 3.8% |
| EPS (diluted) | $1.52 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | $4.1B | — | ||
| Q4 25 | $4.2B | $2.4B | ||
| Q3 25 | $4.2B | $2.4B | ||
| Q2 25 | $4.0B | $2.5B | ||
| Q1 25 | $3.7B | $2.2B | ||
| Q4 24 | $4.0B | $2.3B | ||
| Q3 24 | $4.0B | $2.4B | ||
| Q2 24 | $4.0B | $2.4B |
| Q2 26 | $432.6M | — | ||
| Q4 25 | $563.9M | $603.0M | ||
| Q3 25 | $585.0M | $721.0M | ||
| Q2 25 | $524.2M | $718.0M | ||
| Q1 25 | $402.5M | $631.0M | ||
| Q4 24 | $472.9M | $581.0M | ||
| Q3 24 | $736.5M | $682.0M | ||
| Q2 24 | $490.9M | $624.0M |
| Q2 26 | — | — | ||
| Q4 25 | 44.0% | 70.2% | ||
| Q3 25 | 44.8% | 71.5% | ||
| Q2 25 | 44.8% | 73.6% | ||
| Q1 25 | 44.2% | 72.0% | ||
| Q4 24 | 43.3% | 69.5% | ||
| Q3 24 | 43.4% | 70.6% | ||
| Q2 24 | 43.8% | 71.7% |
| Q2 26 | 15.3% | — | ||
| Q4 25 | 17.0% | 31.9% | ||
| Q3 25 | 18.3% | 37.0% | ||
| Q2 25 | 17.6% | 36.7% | ||
| Q1 25 | 15.0% | 36.5% | ||
| Q4 24 | 14.6% | 31.6% | ||
| Q3 24 | 26.1% | 36.6% | ||
| Q2 24 | 16.5% | 33.0% |
| Q2 26 | 10.6% | — | ||
| Q4 25 | 13.4% | 25.3% | ||
| Q3 25 | 14.0% | 30.0% | ||
| Q2 25 | 13.0% | 29.2% | ||
| Q1 25 | 10.9% | 28.4% | ||
| Q4 24 | 11.8% | 25.1% | ||
| Q3 24 | 18.4% | 28.6% | ||
| Q2 24 | 12.3% | 26.4% |
| Q2 26 | $1.52 | — | ||
| Q4 25 | $1.98 | $1.37 | ||
| Q3 25 | $2.05 | $1.63 | ||
| Q2 25 | $1.84 | $1.61 | ||
| Q1 25 | $1.41 | $1.41 | ||
| Q4 24 | $1.65 | $1.29 | ||
| Q3 24 | $2.58 | $1.50 | ||
| Q2 24 | $1.71 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $519.8K | — |
| Total DebtLower is stronger | $8.5M | — |
| Stockholders' EquityBook value | $10.0M | $3.3B |
| Total Assets | $25.0M | $15.5B |
| Debt / EquityLower = less leverage | 0.85× | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $519.8K | — | ||
| Q4 25 | $646.2M | — | ||
| Q3 25 | $2.0B | $2.1B | ||
| Q2 25 | $1.9B | $1.4B | ||
| Q1 25 | $1.2B | $1.7B | ||
| Q4 24 | $1.3B | $2.0B | ||
| Q3 24 | $1.3B | $1.7B | ||
| Q2 24 | $384.0M | $1.6B |
| Q2 26 | $8.5M | — | ||
| Q4 25 | $7.4B | — | ||
| Q3 25 | $8.1B | — | ||
| Q2 25 | $7.5B | — | ||
| Q1 25 | $7.0B | — | ||
| Q4 24 | $6.9B | — | ||
| Q3 24 | $7.0B | — | ||
| Q2 24 | $7.5B | — |
| Q2 26 | $10.0M | — | ||
| Q4 25 | $9.8B | $3.3B | ||
| Q3 25 | $9.7B | $5.4B | ||
| Q2 25 | $9.3B | $5.0B | ||
| Q1 25 | $8.9B | $4.7B | ||
| Q4 24 | $8.8B | $4.8B | ||
| Q3 24 | $8.5B | $5.2B | ||
| Q2 24 | $8.3B | $5.0B |
| Q2 26 | $25.0M | — | ||
| Q4 25 | $24.7B | $15.5B | ||
| Q3 25 | $23.9B | $15.2B | ||
| Q2 25 | $23.7B | $14.5B | ||
| Q1 25 | $22.4B | $14.1B | ||
| Q4 24 | $22.4B | $14.2B | ||
| Q3 24 | $22.1B | $14.4B | ||
| Q2 24 | $21.5B | $14.2B |
| Q2 26 | 0.85× | — | ||
| Q4 25 | 0.75× | — | ||
| Q3 25 | 0.83× | — | ||
| Q2 25 | 0.81× | — | ||
| Q1 25 | 0.79× | — | ||
| Q4 24 | 0.79× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.91× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $893.0M |
| Free Cash FlowOCF − Capex | — | $732.0M |
| FCF MarginFCF / Revenue | — | 30.7% |
| Capex IntensityCapex / Revenue | — | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | — | ||
| Q4 25 | $1.1B | $893.0M | ||
| Q3 25 | $791.3M | $938.0M | ||
| Q2 25 | $701.8M | $486.0M | ||
| Q1 25 | $369.4M | $587.0M | ||
| Q4 24 | $766.7M | $905.0M | ||
| Q3 24 | $786.7M | $951.0M | ||
| Q2 24 | $611.1M | $502.0M |
| Q2 26 | — | — | ||
| Q4 25 | $758.0M | $732.0M | ||
| Q3 25 | $529.7M | $805.0M | ||
| Q2 25 | $485.1M | $308.0M | ||
| Q1 25 | $131.5M | $438.0M | ||
| Q4 24 | $407.0M | $689.0M | ||
| Q3 24 | $550.3M | $784.0M | ||
| Q2 24 | $414.2M | $370.0M |
| Q2 26 | — | — | ||
| Q4 25 | 18.1% | 30.7% | ||
| Q3 25 | 12.7% | 33.5% | ||
| Q2 25 | 12.1% | 12.5% | ||
| Q1 25 | 3.6% | 19.7% | ||
| Q4 24 | 10.2% | 29.7% | ||
| Q3 24 | 13.8% | 32.8% | ||
| Q2 24 | 10.4% | 15.7% |
| Q2 26 | — | — | ||
| Q4 25 | 7.9% | 6.7% | ||
| Q3 25 | 6.3% | 5.5% | ||
| Q2 25 | 5.4% | 7.2% | ||
| Q1 25 | 6.4% | 6.7% | ||
| Q4 24 | 9.0% | 9.3% | ||
| Q3 24 | 5.9% | 7.0% | ||
| Q2 24 | 4.9% | 5.6% |
| Q2 26 | — | — | ||
| Q4 25 | 1.93× | 1.48× | ||
| Q3 25 | 1.35× | 1.30× | ||
| Q2 25 | 1.34× | 0.68× | ||
| Q1 25 | 0.92× | 0.93× | ||
| Q4 24 | 1.62× | 1.56× | ||
| Q3 24 | 1.07× | 1.39× | ||
| Q2 24 | 1.24× | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ECL
| Product and equipment sales | $3.2B | 78% |
| Service and lease sales | $891.5M | 22% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
